BEACON Cephalosporin Limited

At BEACON Pharmaceuticals, we are excited to introduce a multitude of upcoming facilities that will soon shape the future. We constantly strive for innovative advancements that will redefine healthcare excellence. Currently, BEACON is working on the development of 5 medicinal facilities worth over 1300 Cr.

• Oncology Plant II

The development of a new FDA compliant oncology plant is expected to enhance our export potentiality to higher regulated countries like USA, Europe, Australia. It can widen the scope of export sales to US$ 1 billion. German consultation firm Glatt is working on the design and development of the new plant. It is expected to widen the scope of export sales to US$ 1 billion.

• General Facility

A new general facility is under the works for the production of export products only.

• API facility

A new API plant is being established with the technical support of globally reputed foreign company. It will focus on manufacturing API for oncololgy and general products.

• Biological Product manufacturing facility

This facility will be dedicated for the production of monoclonal antibodies (MAbs) that are usually used for cancer treatment.

• Ereba Capsule

Ereba Capsules Ltd. is a sister concern of BEACON Pharmaceuticals PLC and it is the first company in Bangladesh involved in the manufacturing of empty hard gelatin capsule shell. The formulation contains Halal certified Bovine Gelatin while the manufacturing process adheres to technology with USDMF and CEP grade materials.

Our upcoming facilities

Beacon Pharmaceuticals' upcoming facilities